Is there a role for incorporating local therapy into the management of oligometastatic EGFR-mutant NSCLC with curative intent?

I don’t think there is such a thing as curative intent oligometastatic therapy. That said, consolidative SBRT to 1-3 safe lesions for osimertinib responders seems very reasonable